

# Resource Summary Report

Generated by [nidm-terms](#) on Aug 23, 2026

## Stat5 (pY694)

RRID:AB\_11154412

Type: Antibody

---

### Proper Citation

BD Biosciences Cat# 562076, RRID:AB\_11154412

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_11154412](http://antibodyregistry.org/AB_11154412)

**Proper Citation:** BD Biosciences Cat# 562076, RRID:AB\_11154412

**Target Antigen:** Stat5 (pY694)

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Intracellular staining (flow Cytotoxicityometry)

**Antibody Name:** Stat5 (pY694)

**Description:** This monoclonal targets Stat5 (pY694)

**Target Organism:** human

**Antibody ID:** AB\_11154412

**Vendor:** BD Biosciences

**Catalog Number:** 562076

**Record Creation Time:** 20250819T232526+0000

**Record Last Update:** 20250820T051742+0000

---

### Ratings and Alerts

No rating or validation information has been found for Stat5 (pY694).

No alerts have been found for Stat5 (pY694).

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 8 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [nidm-terms](#) .

Jin Z, et al. (2026) Development of a novel tyrosine kinase 2 inhibitor ARTS-011 and its first-in-human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects. British journal of pharmacology, 183(11), 3074.

Wang L, et al. (2025) CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. Cell reports. Medicine, 6(1), 101889.

Silver AB, et al. (2023) An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2. Cell reports. Medicine, 4(11), 101289.

Fang Z, et al. (2023) Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis. Nature communications, 14(1), 7725.

Kan WL, et al. (2023) Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia. Cancer discovery, 13(8), 1922.

VanDyke D, et al. (2022) Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell reports, 41(3), 111478.

Wagner JA, et al. (2020) Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity. Cell reports, 31(9), 107720.

Berrien-Elliott MM, et al. (2019) MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. Immunity, 51(3), 479.